🇮🇹 REC.MI — Recordati Industria Chimica e Farmaceutica S.p.A.

Salud Mantener
← Volver

Precio actual

53,25 EUR

Máx. histórico

60,95

631 días

Split 4:1 del 18/04/2005

Caída desde máximo

-12,63%

Rango 52 semanas

43,76 – 54,45

Variación hoy

+0,38%

Cierre anterior

53,05

Rango de hoy

52,95 – 53,05

Volumen hoy

283.335

Peor caída histórica

-102,73%

15/02/1996 → 09/05/1996

Aún sin recuperar

Volatilidad anualizada ⓘ

242.233.592.934,14%

Información
Nombre completo
Recordati Industria Chimica e Farmaceutica S.p.A.
Divisa
EUR
Mercado
Milan
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
4.700
PER ⓘ
22,37 (puede no estar actualizado)
Dividend yield
2,67% (puede no estar actualizado)
Precio objetivo analistas
56,73 EUR (puede no estar actualizado)
Primera cotización
24/03/1995
Precio actualizado
hace 12 horas
Sobre la empresa

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing's syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.

Dividendos repartidos Total últimos 12 meses: 1,3400 EUR · Yield: 2,52%
Fecha de pago Importe por participación
18/05/2026 0,7100 EUR
24/11/2025 0,6300 EUR
19/05/2025 0,6700 EUR
18/11/2024 0,6000 EUR
20/05/2024 0,6300 EUR
20/11/2023 0,5700 EUR
22/05/2023 0,6000 EUR
21/11/2022 0,5500 EUR
23/05/2022 0,5700 EUR
22/11/2021 0,5300 EUR
24/05/2021 0,5500 EUR
23/11/2020 0,5000 EUR
18/05/2020 0,5200 EUR
18/11/2019 0,4800 EUR
23/04/2019 0,4700 EUR
Splits Registrados en el histórico de precios
Fecha Ratio
18/04/2005 4:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
18/12/2013 9,92 10,18 9,89 10,07 +1,51% 2,92% 132.901
17/12/2013 10,04 10,10 9,89 9,92 -1,39% 2,14% 158.594
16/12/2013 9,83 10,14 9,83 10,06 +1,41% 3,15% 172.104
13/12/2013 9,78 9,97 9,69 9,92 +1,43% 2,86% 159.374
12/12/2013 9,82 9,84 9,45 9,78 -0,41% 3,97% 413.114
11/12/2013 10,07 10,07 9,75 9,82 -1,80% 3,23% 177.783
10/12/2013 9,83 10,07 9,83 10,00 +0,50% 2,44% 233.341
09/12/2013 10,19 10,32 9,85 9,95 -1,49% 4,61% 296.198
06/12/2013 10,27 10,38 10,04 10,10 -1,66% 3,31% 126.422
05/12/2013 10,44 10,57 10,22 10,27 -0,87% 3,35% 286.420
04/12/2013 10,36 10,45 10,34 10,36 +0,19% 1,06% 80.402
03/12/2013 10,35 10,63 10,34 10,34 -0,67% 2,80% 280.235
02/12/2013 10,50 10,50 10,22 10,41 -0,38% 2,67% 138.531
29/11/2013 10,53 10,62 10,30 10,45 -0,57% 3,04% 127.236
28/11/2013 10,45 10,71 10,45 10,51 +0,19% 2,49% 213.001
27/11/2013 10,35 10,50 10,27 10,49 +1,45% 2,22% 179.178
26/11/2013 10,32 10,44 10,20 10,34 +0,88% 2,33% 182.770
25/11/2013 10,28 10,35 10,10 10,25 -0,29% 2,43% 200.994
22/11/2013 10,12 10,28 10,00 10,28 +1,58% 2,77% 153.127
21/11/2013 10,12 10,12 9,80 10,12 +1,91% 3,16% 191.259
20/11/2013 10,17 10,17 9,93 9,93 -1,59% 2,36% 144.338
19/11/2013 10,07 10,24 9,95 10,09 +1,00% 2,93% 383.518
18/11/2013 10,05 10,19 9,83 9,99 -0,99% 3,63% 406.351
15/11/2013 10,17 10,24 10,08 10,09 -0,20% 1,57% 249.537
14/11/2013 10,19 10,28 10,05 10,11 -0,79% 2,26% 68.427
13/11/2013 10,36 10,36 10,15 10,19 -1,55% 2,03% 90.306
12/11/2013 10,25 10,35 10,17 10,35 +0,98% 1,76% 113.250
11/11/2013 10,25 10,25 10,25 10,25 +1,28% 0,00% 11.257
08/11/2013 10,43 10,45 10,08 10,12 -2,97% 3,55% 501.944
07/11/2013 10,44 10,57 10,29 10,43 +0,77% 2,68% 553.968